HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

WEB 2347: pharmacology of a new very potent and long acting hetrazepinoic PAF-antagonist and its action in repeatedly sensitized guinea-pigs.

Abstract
WEB 2347 is a new hetrazepine which is superior to the previously described paf-antagonists WEB 2086 (apafant) and WEB 2170 (bepafant). This refers to both potency in vitro and in vivo (particularly after oral administration: e.g. the ED50 after oral administration is about 100 times less for WEB 2347 than for WEB 2086 to antagonize paf-induced hypotension in the rat) and duration of action (t1/2 = 41 h in the guinea pig and about 10 h in the rat after p.o. administration). Furthermore the role of paf in active anaphylaxis in vivo, even after repeated microshock, is strengthened.
AuthorsH O Heuer
JournalJournal of lipid mediators (J Lipid Mediat) Vol. 4 Issue 1 Pg. 39-44 ( 1991) ISSN: 0921-8319 [Print] Netherlands
PMID1893086 (Publication Type: Journal Article)
Chemical References
  • Azepines
  • Platelet Activating Factor
  • Triazoles
  • WEB 2347
  • bepafant
Topics
  • Administration, Oral
  • Anaphylaxis (physiopathology)
  • Animals
  • Azepines (administration & dosage, pharmacology)
  • Bronchoconstriction (drug effects)
  • Guinea Pigs
  • Hypotension (physiopathology)
  • Immunization (methods)
  • Platelet Activating Factor (antagonists & inhibitors)
  • Platelet Aggregation (drug effects)
  • Rabbits
  • Rats
  • Rats, Inbred Strains
  • Time Factors
  • Triazoles (administration & dosage, pharmacology)

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: